Zimycan distribution
This article was originally published in The Tan Sheet
Executive Summary
Ft. Worth, Texas-based Healthpoint gets exclusive rights to market Barrier Therapeutics' antifungal ointment Zimycan to healthcare institutions in the U.S. and Canada under an agreement announced Sept. 13. Barrier cites Healthpoint's tissue management division as a good match for the product. The firm announced positive Phase III trial results for the candida-associated diaper rash cream in August after licensing the drug from Johnson & Johnson, where it had failed to gain approval as an OTC (1"The Tan Sheet" Aug. 16, 2004, p. 9). Barrier's NDA for Zimycan is currently pending at FDA...
Ft. Worth, Texas-based Healthpoint gets exclusive rights to market Barrier Therapeutics' antifungal ointment Zimycan to healthcare institutions in the U.S. and Canada under an agreement announced Sept. 13. Barrier cites Healthpoint's tissue management division as a good match for the product. The firm announced positive Phase III trial results for the candida-associated diaper rash cream in August after licensing the drug from Johnson & Johnson, where it had failed to gain approval as an OTC (1 (Also see "OTC Misfire Salvaged As Rx Prospect: Barrier Touts Antifungal Zimycan Trial" - Pink Sheet, 16 Aug, 2004.), p. 9). Barrier's NDA for Zimycan is currently pending at FDA.... |